Herantis Pharma Plc’s Financial Calendar and Annual General Meeting for 2022

Herantis Pharma Plc, Company Release, 15 December 2021 at 09:00 EET

Herantis Pharma Plc (“Herantis”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, hereby publishes the financial calendar for 2022:

Financial year 2021
Quiet period before H2 and FY 2021 report February 1 – March 3, 2022
H2 and FY 2021 report March 3, 2022
Annual report 2021 March 23, 2022
Financial year 2022
Deadline for submission of proposal for the AGM February 21, 2022
Annual General Meeting (AGM) April 21, 2022
Quiet period before H1 2022 report July 26 – August 25, 2022
H1 2022 report August 25, 2022

The dates are subject to change.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. rhCDNF (a biological protein) is Herantis’ lead program and a clinical stage asset; and HER-096 (a synthetic peptide version of CDNF) is Herantis’ follow-on program. CDNF is a natural protein that occurs naturally in the body whose natural role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. Both rhCDNF and HER-096, via their multimodal mechanism of action, have the potential to improve neuronal survival and stop the progression of Parkinson’s and other neurodegenerative diseases with a significant therapeutic impact on the quality of patients’ lives.